Basel, October 6, 2017 – Alcon, the all-around baton in eye affliction and a assay of Novartis, has accomplished European CE Mark for the Clareon® IOL with the AutonoMe(TM) commitment system. AutonoMe(TM) is the first-and-only automated, disposable, pre-loaded IOL commitment arrangement that enables absolute commitment of the IOL into the capsular bag in patients adeptness avalanche surgery[1-2]. The new accessory is actuality alien with the Clareon® IOL, a new BioMaterial with an avant-garde architecture that enables sharp, brittle vision; low bend glare; and, incomparable optic clarity*. These new innovations, alternating with acknowledging accurate data, will be presented at the XXXV assembly of the European Society of Avalanche & Refractive Surgeons (ESCRS) demography abode October 7 – 11 in Lisbon, Portugal.
“With the addition of Clareon® AutonoMe(TM), we are appreciative to bare our latest innovations to account doctors and their patients adeptness avalanche surgery,” said Mike Ball, Chief Executive Officer, Alcon. “Throughout Alcon’s history, we accept formed with doctors to enhance and transform the way avalanche anaplasty is performed. Clareon® AutonoMe(TM) builds aloft the absolute bequest of AcrySof® by alms avalanche surgeons easy, automatic ascendancy of IOL commitment with the newest optic material.”
The AutonoMe(TM) commitment system, preloaded with the Clareon® IOL, is advised with advancements advised to account both surgeons and avalanche patients. Its automatic CO2-powered commitment apparatus and intuitive, ergonomic architecture acquiesce absolute and simplified single-handed ascendancy of IOL adjustment during avalanche surgery[1-2].
“Comfort and adeptness during the avalanche anaplasty are key to accomplishing bigger outcomes. This new accessory is accepted to advance the action and ultimately to abate surgical time,” said Prof. Rudolph Nuijts, University of Maastricht, Netherlands. “This is abundant account for surgeons because Clareon® AutonoMe(TM) provides a cutting-edge, automatic and easy-to-use accessory that allows absolute and controlled IOL delivery.”
The Clareon® berserk acrylic IOL, which accustomed CE Mark in May, is fabricated of a patented, avant-garde optic polymer material. Clareon® builds on and maintains the allowances of the accurate AcrySof® belvedere with a new optic BioMaterial that offers avalanche patients incomparable clarity*.
Alcon will present new abstracts on Clareon® via cardboard presentations and cyberbanking posters at ESCRS, including:
Clareon® AutonoMe(TM) is accepted to be commercially accessible to avalanche surgeons in the EU aboriginal aing year. Learn added about these innovations at the Alcon Booth #P272 in the exhibition breadth of the Feira Internacional de Lisboa (FIL) assembly centermost at ESCRS.
About CataractsA avalanche is a clouding of the accustomed lens of the eye that affects vision. As a avalanche develops, the eye’s lens gradually becomes harder and blurred which scatters ablaze application and allows beneath ablaze to canyon through it, appropriately abbreviation the patient’s adeptness to see. The all-inclusive majority of amaurosis action as allotment of accustomed crumbling but radiation exposure, demography steroids, diabetes, and eye agony can advance the development of cataracts.
Additionally, amaurosis can be ancestral and complete and can present anon afterwards birth. Amaurosis are the best accepted age-related eye action and the arch account of preventable amaurosis in adults 55 and older. Amaurosis are advised by surgically removing the eye’s blurred accustomed lens and replacing it with an intraocular lens (IOL). Added than 98 percent of avalanche surgeries are advised acknowledged and patients can usually acknowledgment to their accustomed routines absolute anon afterwards surgery.
Important Advice About the Clareon® IOL with the AutonoMe(TM) Commitment SystemAs with any surgical procedure, there is accident involved. Abeyant complications accompanying avalanche and/or IOL article anaplasty may include, but are not bound to, the following: lens epithelial corpuscle on-growth, corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, brief or assiduous glaucoma. Surgeons should use accurate preoperative appraisal and complete analytic judgement to adjudge the benefit/risk arrangement afore implanting a lens in a accommodating with one or added of the altitude articular in the artefact labeling. Only Alcon-qualified ophthalmic viscosurgical accessories (OVDs) should be acclimated with Clareon® AutonoMe(TM). The use of an amateur OVD may account accident to the lens and abeyant complications during the article process.
DisclaimerThis columnist absolution contains advanced statements aural the acceptation of the United States Private Securities Litigation Reform Act of 1995. Advanced statements can about be articular by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or agnate terms, or by accurate or adumbrated discussions apropos abeyant business approvals, new break or labeling for the investigational or accustomed articles declared in this columnist release, or apropos abeyant approaching revenues from such products. You should not abode disproportionate assurance on these statements. Such advanced statements are based on our accepted behavior and expectations apropos approaching events, and are accountable to cogent accepted and alien risks and uncertainties. Should one or added of these risks or uncertainties materialize, or should basal assumptions prove incorrect, absolute after-effects may alter materially from those set alternating in the advanced statements. There can be no agreement that the investigational or accustomed articles declared in this columnist absolution will be submitted or accustomed for auction or for any added break or labeling in any market, or at any accurate time. Nor can there be any agreement that such articles will be commercially acknowledged in the future. In particular, our expectations apropos such articles could be afflicted by, amid added things, the uncertainties inherent in assay and development, including analytic balloon after-effects and added assay of absolute analytic data; authoritative accomplishments or delays or government adjustment generally; our adeptness to admission or advance proprietary bookish acreage protection; the accurate prescribing preferences of physicians and patients; all-around trends against bloom affliction amount containment, including government, payor and accepted accessible appraisement and agreement pressures; accepted bread-and-er and industry conditions, including the furnishings of the agilely anemic bread-and-er and banking ambiance in abounding countries; safety, affection or accomplishment issues, and added risks and factors referred to in Novartis AG’s accepted Form 20-F on book with the US Securities and Exchange Commission. Novartis is accouterment the advice in this columnist absolution as of this date and does not undertake any obligation to amend any advanced statements independent in this columnist absolution as a aftereffect of new information, approaching contest or otherwise.
About AlconAlcon is the all-around baton in eye care. As a assay of Novartis, we action the broadest portfolio of articles to enhance afterimage and advance people’s lives. Our articles blow the lives of added than 260 actor bodies anniversary year active with altitude like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions added who are cat-and-mouse for solutions to accommodated their eye affliction needs. Our purpose is reimagining eye care, and we do this through avant-garde products, partnerships with eye affliction professionals and programs that enhance admission to affection eye care. Learn added at www.alcon.com.
Alcon is on Facebook. Like us at www.facebook.com/AlconEyeCare
About NovartisNovartis provides avant-garde healthcare solutions that abode the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a adapted portfolio to best accommodated these needs: avant-garde medicines, cost-saving all-encompassing and biosimilar pharmaceuticals and eye care. Novartis has arch positions globally in anniversary of these areas. In 2016, the Group accomplished net sales of USD 48.5 billion, while R&D throughout the Group amounted to about USD 9.0 billion. Novartis Group companies apply about 119,000 full-time-equivalent associates. Novartis articles are awash in about 155 countries about the world. For added information, amuse appointment http://www.novartis.com.
Novartis is on Twitter. Sign up to chase @Novartis at http://twitter.com/novartisFor Novartis multimedia content, amuse appointment www.novartis.com/news/media-libraryFor questions about the armpit or appropriate registration, amuse acquaintance [email protected]
*Based on accumulated after-effects from in vitro evaluations of haze, SSNGs and glistenings compared to TECNIS§ OptiBlue§ ZCB00V (Abbott),TECNIS§ ZCB00 (Abbott), Eternity§ Accustomed Uni W-60 (Santen), Vivinex§ XY-1 (HOYA) and enVista§ MX60 (B&L; Bausch & Lomb).
§ Trademarks are the acreage of their corresponding owners
# # #
Novartis Media RelationsCentral media line: 41 61 324 2200E-mail: [email protected]
Novartis Broker RelationsCentral broker relations line: 41 61 324 7944E-mail: [email protected]
How De 8 Form Pdf Can Increase Your Profit! | De 8 Form Pdf – de 2501 form pdf
| Encouraged to help my website, within this moment I am going to demonstrate with regards to de 2501 form pdf